John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 300 shares at $7.52 ($2K) on 2022-03-30, disclosed to the SEC on 2022-04-01.
Scheduled sale ($2k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |